252 related articles for article (PubMed ID: 24440991)
21. [Nasal vaccines].
Kido H; Mizuno D; Takei T
Nihon Rinsho; 2008 Oct; 66(10):1881-7. PubMed ID: 18939485
[TBL] [Abstract][Full Text] [Related]
22. Mucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?
Jakobsen H; Jonsdottir I
Scand J Immunol; 2003 Aug; 58(2):119-28. PubMed ID: 12869132
[TBL] [Abstract][Full Text] [Related]
23. Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.
Takaki H; Ichimiya S; Matsumoto M; Seya T
J Innate Immun; 2018; 10(5-6):515-521. PubMed ID: 29860261
[TBL] [Abstract][Full Text] [Related]
24. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.
Lynch JM; Briles DE; Metzger DW
Infect Immun; 2003 Aug; 71(8):4780-8. PubMed ID: 12874361
[TBL] [Abstract][Full Text] [Related]
25. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K
Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790
[TBL] [Abstract][Full Text] [Related]
26. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.
Rochereau N; Pavot V; Verrier B; Jospin F; Ensinas A; Genin C; Corthésy B; Paul S
J Allergy Clin Immunol; 2016 Jan; 137(1):214-222.e2. PubMed ID: 26414879
[TBL] [Abstract][Full Text] [Related]
27. Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection.
Wright AK; Briles DE; Metzger DW; Gordon SB
Vaccine; 2008 Sep; 26(38):4893-903. PubMed ID: 18602438
[TBL] [Abstract][Full Text] [Related]
28. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.
Tamura S; Kurata T
Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947
[TBL] [Abstract][Full Text] [Related]
29. Impaired innate mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae colonization.
Krone CL; Trzciński K; Zborowski T; Sanders EA; Bogaert D
Infect Immun; 2013 Dec; 81(12):4615-25. PubMed ID: 24082075
[TBL] [Abstract][Full Text] [Related]
30. Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone.
Guy B; Fourage S; Hessler C; Sanchez V; Millet MJ
Clin Diagn Lab Immunol; 1998 Sep; 5(5):732-6. PubMed ID: 9729544
[TBL] [Abstract][Full Text] [Related]
31. Induction of secretory immunity and memory at mucosal surfaces.
Brandtzaeg P
Vaccine; 2007 Jul; 25(30):5467-84. PubMed ID: 17227687
[TBL] [Abstract][Full Text] [Related]
32. Understanding host immune responses to pneumococcal proteins in the upper respiratory tract to develop serotype-independent pneumococcal vaccines.
Lagousi T; Basdeki P; De Jonge MI; Spoulou V
Expert Rev Vaccines; 2020 Oct; 19(10):959-972. PubMed ID: 33107359
[No Abstract] [Full Text] [Related]
33. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
[TBL] [Abstract][Full Text] [Related]
34. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
[TBL] [Abstract][Full Text] [Related]
35. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
[TBL] [Abstract][Full Text] [Related]
36. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
37. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A.
Oliveira ML; Arêas AP; Campos IB; Monedero V; Perez-Martínez G; Miyaji EN; Leite LC; Aires KA; Lee Ho P
Microbes Infect; 2006 Apr; 8(4):1016-24. PubMed ID: 16549380
[TBL] [Abstract][Full Text] [Related]
38. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
[TBL] [Abstract][Full Text] [Related]
39. Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and
LeMessurier KS; Tiwary M; Morin NP; Samarasinghe AE
Front Immunol; 2020; 11():3. PubMed ID: 32117216
[TBL] [Abstract][Full Text] [Related]
40. Salivary IgA enhancement strategy for development of a nasal-spray anti-caries mucosal vaccine.
Yan H
Sci China Life Sci; 2013 May; 56(5):406-13. PubMed ID: 23633072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
